Stock GNLX GENELUX CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Genelux Corporation

Equities

GNLX

US36870H1032

Delayed Nasdaq
Other stock markets
 01:27:08 29/05/2024 am IST 		5-day change 1st Jan Change
2.775 USD +5.92% Intraday chart for Genelux Corporation -44.62% -80.16%
24/05 Top Midday Decliners MT
24/05 Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
GL
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
AQ
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
GL
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
GL
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
GL
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
GL
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
GL
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
AQ
Genelux Corporation Announces New Chief Financial Officer
GL
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
GL
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
AQ
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
GL
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
AQ
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
GL
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
AQ
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
GL
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
GL
Genelux Corporation Set to Join the Russell 3000 and Russell 2000 Indexes Effective June 26, 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GNLX Stock
  4. News Genelux Corporation
  5. Press Releases